Skip to content
Clinical Trials – home
Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 86

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Synovial sarcoma+1

Recruiting

Study on Pasireotide for Patients with Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Pasireotide
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Renal cancer+2

Recruiting

Study on Using EMI-137 for Intraoperative Visualization in Patients with Penile and Tongue Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ac-Ala-Gly-Ser-Cys(1)-Tyr-Cys(2)-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys(2)-Trp-Cys(1)-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys(Unk)-Nh2 Conjugated To Cy5 Dye
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Colon cancer

Recruiting

Study on Pre-Surgery Immunotherapy with Relatlimab, Anti-IL-8 mAb, and Ipilimumab for Early-Stage Colon Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Celecoxib
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on Trastuzumab, Pertuzumab, and Tucatinib for Patients with Stage II-III HER2-Positive Breast Cancer Without Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Neuroblastoma+1

Recruiting

Study of ABTL0812, Irinotecan, and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Irinotecan
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Vaestra Goetalandsregionen

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on Fludarabine, Melphalan, and Radiation for Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Preparing for Stem Cell Transplant.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.